Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medpace HoldingsMEDP -0.51%97 EV-to-OCF is 20.93 as of Aug. 17, 2026, which is 17% above its 10-year median of 17.91. GuruFocus rates MEDP with a GF Score™ of 97/100 and a GF Value™ of $532.79 (Fairly Valued). The stock has 2 warning signs investors should review. Among 212 Medical Diagnostics & Research companies, Medpace Holdings ranks worse than 75.47% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Medpace Holdings's Enterprise Value is $15,751 Mil.
Medpace Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $753 Mil. Therefore, Medpace Holdings's EV-to-OCF for today is 20.93.
The historical rank and industry rank for Medpace Holdings's EV-to-OCF or its related term are showing as below:
MEDP'
s EV-to-OCF Range Over the Past 10 Years
Min: 11.55 Med: 17.91 Max: 38.83
Current: 20.93
During the past 13 years, the highest EV-to-OCF of Medpace Holdings was 38.83. The lowest was 11.55. And the median was 17.91.
MEDP's EV-to-OCF is ranked worse than 75.47% of 212
companies
in the Medical Diagnostics & Research industry
Industry Median: 6.235
vs MEDP: 20.93
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Medpace Holdings's PE Ratio (TTM) for today is calculated as:
Medpace Holdings's share price for today is $578.02.
Medpace Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $17.060.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Medpace Holdings EV-to-OCF Related Terms
Medpace Holdings EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Medpace Holdings's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Medpace Holdings's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medpace Holdings EV-to-OCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Medpace Holdings's EV-to-OCF falls into.
Medpace Holdings's current Enterprise Value is $15,751 Mil.
Medpace Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $753 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medpace Holdings (MEDP) has a EV-to-OCF of 20.93 as of Aug. 17, 2026. This is 17% above median its historical median of 17.91. Over the past decade, Medpace Holdings' EV-to-OCF has ranged from 11.55 to 38.83. According to the industry distribution chart, Medpace Holdings ranks #160 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 75.5%.
Is Medpace Holdings' EV-to-OCF too high?
Medpace Holdings' current EV-to-OCF of 20.93 is 17% above median its 10-year median of 17.91. Over the past 10 years, this metric has ranged from a low of 11.55 to a high of 38.83. The Medical Diagnostics & Research industry median EV-to-OCF is 6.24. Medpace Holdings' value of 20.93 is 235.7% above this industry median. Based on the distribution chart, Medpace Holdings ranks #160 out of 212 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Medpace Holdings has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medpace Holdings' EV-to-OCF compare to GH and ICLR?
According to the Medical Diagnostics & Research industry distribution chart, Medpace Holdings ranks #160 out of 212 companies for EV-to-OCF. This places Medpace Holdings in the lower half of its industry. The industry median EV-to-OCF is 6.24. Medpace Holdings' value of 20.93 is 235.7% above this benchmark. Historically, Medpace Holdings' own EV-to-OCF has ranged from 11.55 to 38.83 over the past decade. While the company's 10-year median is 17.91 vs. the industry median of 6.24, Medpace Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Diagnostics & Research company?
The median EV-to-OCF among Medical Diagnostics & Research companies is 6.24, based on 212 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medpace Holdings's current EV-to-OCF of 20.93 is 235.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median EV-to-OCF is 6.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medpace Holdings's current EV-to-OCF is 20.93, which is 17% above median its own 10-year median of 17.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medpace Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medpace Holdings (MEDP) is currently considered Fairly Valued. The stock's GF Value™ is $532.79, compared to a current price of $578.02 — trading 8.5% above its estimated fair value. The current EV-to-OCF is 20.93, which is 17% above median its 10-year median of 17.91 and 235.7% above the Medical Diagnostics & Research industry median of 6.24. Medpace Holdings' overall GF Score™ is 97/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Medpace Holdings (MEDP), the current EV-to-OCF is 20.93 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medpace Holdings (MEDP) Overvalued in 2026?
Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued.
The current stock price of $578.02 is trading 8.5% above its estimated GF Value™ of $532.79.
GuruFocus considers Medpace Holdings to be Fairly Valued.
Key valuation signals for MEDP:
EV-to-OCF: 20.93 (17% above median its 10-year median of 17.91)
GF Value™: $532.79 vs. price of $578.02 (8.5% above fair value)
Industry Position: 235.7% above the Medical Diagnostics & Research median (#160 of 212)
No single metric tells the full story. See the MEDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
97GF Score
Get the complete analysis for MEDP
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDP has been successfully added to your 
